SGLT2I- Evolving Science in the Space of CKD

Speciality: Nephrology

Description:

A warm welcome to all the medical professionals in this exciting session on evolving science in the space of CKD. 

The global prevalence of CKD is substantial with profound implications, healthcare costs, and outcomes. The risk of morbidity and mortality rises sharply as CKD progresses. The vast majority of larger-scale trials in CKD have focussed on Type 2 Diabetes populations.

SGLT2 inhibition has a number of potential direct and downstream effects which may result in beneficial effects on kidney function. SGLT2i CVOTs have consistently shown a reduction in renal endpoints. DAPA-CKD builds upon the evidence for Dapagliflozin in preventing hHF and worsening renal disease in DECLARE and reducing the risk of worsening HF and CV death in DAPA-HF.

Therefore, listen to the webinar, grab the shared knowledge, and follow HiDoc for more such exciting webinar sessions.
 

See More Webinars @ Hidoc Webinars